Arcturus Therapeutics Holdings Inc. (ARCT) Stock

Arcturus Therapeutics Holdings Inc. operates as an advanced-stage clinical biotechnology company specializing in mRNA medicines and vaccines. Founded in 2013 and headquartered in San Diego, California, Arcturus leverages cutting-edge technologies including LUNAR lipid-mediated delivery, STARR mRNA Technology (samRNA), and mRNA drug substance manufacturing.

The company's robust pipeline encompasses RNA therapeutic and vaccine candidates, notably including programs for SARS-CoV-2 (COVID-19) and Influenza. Additionally, Arcturus is advancing treatments for ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type III, and hepatitis B virus through strategic partnerships.

Arcturus' versatile RNA platforms support a range of nucleic acid medicines such as messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. This technological diversity is bolstered by a robust patent portfolio covering its innovations across key global markets including the U.S., Europe, Japan, and China.

Driven by a commitment to scientific excellence and innovation, Arcturus Therapeutics continues to push the boundaries of mRNA-based therapies. By advancing transformative treatments for infectious diseases and genetic disorders, the company aims to improve healthcare outcomes globally and make significant contributions to the field of biotechnology.